Several studies suggest that CDC of B-CLL cells by rituximab is ineffective because of the presence of complement regulatory proteins, including the soluble protective protein complement factor H (CFH), that inhibit CDC [4–6]. Here, CFH is linked to B-cell chronic lymphocytic leukemia.